DWTX - Dogwood Therapeutics, Inc.

4.05
-0.200   -4.938%

Share volume: 70,059
Last Updated: 04-07-2025
Pharmaceutical Products/Pharmaceutical Preparations: 0.00%

PREVIOUS CLOSE
CHG
CHG%
$4.25
-0.20
-0.05%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
28%
Profitability 0%
Dept financing 34%
Liquidity 50%
Performance 50%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-3.11%
1 Month
-52.01%
3 Months
70.17%
6 Months
2,512.90%
1 Year
799.00%
2 Year
595.52%
Key data
Stock price
$4.05
P/E Ratio 
0.00
DAY RANGE
$3.80 - $4.08
EPS 
-$2.17
52 WEEK RANGE
$0.13 - $29.28
52 WEEK CHANGE
$772.09
MARKET CAP 
4.719 M
YIELD 
N/A
SHARES OUTSTANDING 
0.000
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-14-2025
BETA 
6.43
PUBLIC FLOAT 
N/A
AVERAGE 10 VOLUME 
$141,064
AVERAGE 30 VOLUME 
$1,702,522
Company detail
CEO: Greg Duncan
Region: US
Website: dwtx.com
Employees: 5
IPO year: 2020
Issue type:
Market: NASDAQ
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Dogwood Therapeutics Inc. focuses on developing antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia.

Recent news
loading